[NCI CIRB] EA2165 - A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
The purpose of this study is to find if adding the study drug, nivolumab after standard chemotherapy and radiation will prevent the anal cancer from returning
- Participants must have stage IIB, IIIA, IIIB, or IIIC squamous cell carcinoma of the anus of anorectum
18 - 99
Healthy Volunteers Needed
Duration of Participation
Participants will be on study for up to 5 years from the time of study entry through follow up.
Knight Information Line - firstname.lastname@example.org or 503-494-1080